These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 14563790

  • 1. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.
    Richter T, Mürdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, Zanger UM.
    J Pharmacol Exp Ther; 2004 Jan; 308(1):189-97. PubMed ID: 14563790
    [Abstract] [Full Text] [Related]

  • 2. Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel.
    Nishiya Y, Hagihara K, Ito T, Tajima M, Miura S, Kurihara A, Farid NA, Ikeda T.
    Drug Metab Dispos; 2009 Mar; 37(3):589-93. PubMed ID: 19047469
    [Abstract] [Full Text] [Related]

  • 3. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.
    Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, Pelkonen O.
    Drug Metab Dispos; 2004 Jun; 32(6):626-31. PubMed ID: 15155554
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based.
    Richter T, Schwab M, Eichelbaum M, Zanger UM.
    Biochem Pharmacol; 2005 Feb 01; 69(3):517-24. PubMed ID: 15652242
    [Abstract] [Full Text] [Related]

  • 5. A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6.
    Walsky RL, Obach RS.
    Drug Metab Dispos; 2007 Nov 01; 35(11):2053-9. PubMed ID: 17682072
    [Abstract] [Full Text] [Related]

  • 6. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
    Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A.
    Drug Metab Dispos; 2010 Jan 01; 38(1):92-9. PubMed ID: 19812348
    [Abstract] [Full Text] [Related]

  • 7. Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel.
    Nishiya Y, Hagihara K, Kurihara A, Okudaira N, Farid NA, Okazaki O, Ikeda T.
    Xenobiotica; 2009 Nov 01; 39(11):836-43. PubMed ID: 19845434
    [Abstract] [Full Text] [Related]

  • 8. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes.
    Bae SK, Cao S, Seo KA, Kim H, Kim MJ, Shon JH, Liu KH, Zhou HH, Shin JG.
    Drug Metab Dispos; 2008 Aug 01; 36(8):1679-88. PubMed ID: 18474675
    [Abstract] [Full Text] [Related]

  • 9. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine.
    Hagihara K, Nishiya Y, Kurihara A, Kazui M, Farid NA, Ikeda T.
    Drug Metab Pharmacokinet; 2008 Aug 01; 23(6):412-20. PubMed ID: 19122335
    [Abstract] [Full Text] [Related]

  • 10. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
    Bae SH, Kwon MJ, Choi EJ, Zheng YF, Yoon KD, Liu KH, Bae SK.
    Chem Biol Interact; 2013 Sep 05; 205(1):11-9. PubMed ID: 23777987
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols.
    Lau AJ, Chang TK.
    Drug Metab Dispos; 2009 Sep 05; 37(9):1931-7. PubMed ID: 19487249
    [Abstract] [Full Text] [Related]

  • 12. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.
    Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K.
    Clin Pharmacol Ther; 2005 Jun 05; 77(6):553-9. PubMed ID: 15961986
    [Abstract] [Full Text] [Related]

  • 13. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
    Xu C, Ogburn ET, Guo Y, Desta Z.
    Drug Metab Dispos; 2012 Apr 05; 40(4):717-25. PubMed ID: 22232427
    [Abstract] [Full Text] [Related]

  • 14. Metabolism of endosulfan-alpha by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4.
    Casabar RC, Wallace AD, Hodgson E, Rose RL.
    Drug Metab Dispos; 2006 Oct 05; 34(10):1779-85. PubMed ID: 16855053
    [Abstract] [Full Text] [Related]

  • 15. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
    Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ.
    Drug Metab Dispos; 2001 Feb 05; 29(2):100-2. PubMed ID: 11159797
    [Abstract] [Full Text] [Related]

  • 16. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
    Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM.
    Drug Metab Dispos; 2000 Oct 05; 28(10):1222-30. PubMed ID: 10997944
    [Abstract] [Full Text] [Related]

  • 17. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro.
    Chang SY, Chen C, Yang Z, Rodrigues AD.
    Drug Metab Dispos; 2009 Aug 05; 37(8):1667-75. PubMed ID: 19454483
    [Abstract] [Full Text] [Related]

  • 18. The development of a cocktail CYP2B6, CYP2C8, and CYP3A5 inhibition assay and a preliminary assessment of utility in a drug discovery setting.
    O'Donnell CJ, Grime K, Courtney P, Slee D, Riley RJ.
    Drug Metab Dispos; 2007 Mar 05; 35(3):381-5. PubMed ID: 17142561
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.